Provide a valuable resource to your clients or customers by linking to this resource page. Just place the following link on your website.
Giazo was a brand name for 1.1 g balsalazide disodium tablets. The brand-name product has been discontinued in the U.S., while generic balsalazide tablets are listed. This tablet formulation is indicated for mildly to moderately active ulcerative colitis in men age 18 or older.
read more about giazo ...Giazo tablets were used to treat active ulcerative colitis of mild to moderate severity in adult men. The tablet indication is limited to men since clinical trials did not demonstrate its benefit in women. Balsalazide capsules have different labeling and should not be assumed to have the same dosing or age criteria.
Balsalazide travels through the digestive tract and is converted in the colon to mesalamine. Mesalamine acts locally to reduce inflammation in the colon lining. Reducing that inflammation can help control ulcerative colitis symptoms.
The labeled tablet dose is three 1.1 g tablets twice daily for up to eight weeks. The tablets can be taken with or without food. Patients are advised to drink adequate fluids and follow the specific prescription instructions.
Diarrhea, anemia, throat discomfort, and urinary tract infection were reported in trials of the tablets. Balsalazide can affect kidney function, so testing is recommended before and during treatment. New or worsening abdominal pain, bloody diarrhea, fever, or rash should be reported promptly since these symptoms can signal an intolerance reaction.
Giazo is listed as a discontinued brand-name product. Generic 1.1 g balsalazide disodium tablets have current labeling.
No. The tablet indication was limited to adult men since benefit was not demonstrated in women during clinical trials.
No. Their strengths, schedules, and labeled populations differ, so follow the prescription for the specific formulation.
Medicines that release mesalamine can cause kidney problems. Testing helps the prescriber watch kidney function during treatment.
Balsalazide. MedlinePlus. https://www.medlineplus.gov/druginfo/meds/a699052.html. Date Accessed October 6, 2026.
Balsalazide (oral route) - Side effects & dosage. Mayo Clinic. https://www.mayoclinic.org/drugs-supplements/balsalazide-oral-route/description/drg-20062119. Date Accessed October 6, 2026.
Balsalazide disodium 1.1 g tablets: Prescribing Information. DailyMed (National Library of Medicine). https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=53d2f754-9f24-47d8-9938-fd2988669f17. Date Accessed October 6, 2026.
Lupin Receives Tentative Approval for Generic Giazo? Tablets - Lupin | Press Release. Lupin. https://www.lupin.com/media/press-releases/lupin-receives-tentative-approval-for-generic-giazo-tablets. Date Accessed October 6, 2026.
Safety and efficacy of a new 3.3 g b.i.d. tablet formulation in patients with mild-to-moderately-active ulcerative colitis: a multicenter, randomized, double-blind, placebo-controlled study. PubMed. https://pubmed.ncbi.nlm.nih.gov/19491859/. Date Accessed October 6, 2026.